Trials / Terminated
TerminatedNCT00975806
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Lenalidomide in Combination With Sunitinib in Subjects With Advanced or Metastatic Renal Cell Carcinoma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to determine the maximum tolerated dose, safety, and effectiveness of lenalidomide (CC-5013) administered in combination with sunitinib as treatment for patients with renal cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenalidomide | Lenalidomide MTD mg by mouth (PO) daily for Days 1- 21 in combination |
| DRUG | Sunitinib | Sunitinib 37.5 mg PO daily on days 1-21 of each 21-day cycle in Cohort A or on days 1-14 in Cohorts F and G |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2009-09-11
- Last updated
- 2019-11-25
- Results posted
- 2014-12-29
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00975806. Inclusion in this directory is not an endorsement.